A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 301–400 of 3,965
Pirfenidone: A Review of Its Use in Idiopathic Pulmonary Fibrosis
Kim, E. S., & Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0350-9 · Cited by 126
Patients With Fibrotic Interstitial Lung Disease Hospitalized for Acute Respiratory Worsening
Moua, T., Westerly, B. D., Dulohery, M. M., Daniels, C. E., Ryu, J. H., & Lim, K. G. (2016) · CHEST Journal · doi:10.1016/j.chest.2015.12.026 · Cited by 118
Neighbors, M., Cabanski, C. R., Ramalingam, T. R., Sheng, X. R., Tew, G. W., Gu, C., Jia, G., Peng, K., Ray, J. M., Ley, B., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30185-1 · Cited by 115
Ahangari, F., Becker, C., Foster, D. G., Chioccioli, M., Nelson, M., Beke, K. M., Wang, X., Justet, A., Adams, T. S., Readhead, B. P., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202010-3832oc · Cited by 124
Nathan, S. D., du Bois, R. M., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Noble, P. W., Sahn, S. A., Valeyre, D., Weycker, D., et al. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.04.008 · Cited by 114
Self-citationCough in idiopathic pulmonary fibrosis
van Manen, M. J. G., Birring, S. S., Vancheri, C., Cottin, V., Renzoni, E. A., Russell, A.-M., & Wijsenbeek, M. S. (2016) · European Respiratory Review · doi:10.1183/16000617.0090-2015 · Cited by 114
Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
Khor, Y. H., Ng, Y., Barnes, H., Goh, N. S. L., McDonald, C. F., & Holland, A. E. (2020) · European Respiratory Review · doi:10.1183/16000617.0158-2019 · Cited by 127
Vainshelboim, B., de Oliveira, J. J. F., Fox, B. D., Soreck, Y., Fruchter, O., & Kramer, M. R. (2015) · Lung · doi:10.1007/s00408-015-9703-0 · Cited by 126
“Long-term effective treatment, apart from lung transplantation, is still limited for most IPF patients despite some encouraging recent findings with pharmacotherapy [1, 3–5].”
ResultIdiopathic non‐specific interstitial pneumonia
Belloli, E. A., Beckford, R., Hadley, R. J., & Flaherty, K. R. (2015) · Respirology · doi:10.1111/resp.12674 · Cited by 126
Joshee, S. R., Vatti, N., & Chang, C. C.-C. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.12.017 · Cited by 142
Salisbury, M. L., Xia, M., Zhou, Y., Murray, S., Tayob, N., Brown, K. K., Wells, A. U., Schmidt, S. L., Martínez, F. J., & Flaherty, K. R. (2015) · CHEST Journal · doi:10.1378/chest.15-0530 · Cited by 124
Ono, M., Ohkouchi, S., Kanehira, M., Tode, N., Kobayashi, M., Ebina, M., Nukiwa, T., Irokawa, T., Ogawa, H., Akaike, T., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.217 · Cited by 111
Russell, A.-M., Ripamonti, E., & Vancheri, C. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0171-y · Cited by 111
Tissue-resident mesenchymal stromal cells: Implications for tissue-specific antifibrotic therapies
Lemos, D. R., & Duffield, J. S. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5174 · Cited by 113
Kalchiem‐Dekel, O., Galvin, J. R., BURKE, A. P., Atamas, S. P., & Todd, N. W. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120476 · Cited by 129
Alysandratos, K., Russo, S. J., Petcherski, A., Taddeo, E. P., Acín‐Pérez, R., Villacorta-Martín, C., Jean, J., Mulugeta, S., Rodríguez, L. R., Blum, B. C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109636 · Cited by 125
“…been a major hurdle in developing effective therapies, and the two currently FDA-approved drugs pirfenidone and nintedanib, both aimed at inhibiting fibrogenic fibroblasts, have been shown to slow but not reverse the progression of lung function decline (King et al., 2014; Richeldi et al., 2014).”
BackgroundRadiation-Induced Lung Fibrosis: Preclinical Animal Models and Therapeutic Strategies
Jin, H. K., Yoo, Y., Kim, Y.-H., Kim, Y., Cho, J., & Lee, Y. (2020) · Cancers · doi:10.3390/cancers12061561 · Cited by 128
“However, regimens for IPF, such as pirfenidone and nintedanib, help to reduce clinical exacerbations that affect pulmonary function [3,4].”
BackgroundTreatment of fibrotic interstitial lung disease: current approaches and future directions
Johannson, K. A., Chaudhuri, N., Adegunsoye, A., & Wolters, P. J. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01826-2 · Cited by 135
Regeneration of functional alveoli by adult human SOX9+ airway basal cell transplantation
Ma, Q., Ma, Y., Dai, X., Ren, T., Fu, Y., Liu, W., Han, Y., Wu, Y., Cheng, Y., Zhang, T., et al. (2018) · Protein & Cell · doi:10.1007/s13238-018-0506-y · Cited by 112
“…signaling modulates SOX9+ BC proliferation To further improve the transplantation efficiency of SOX9+ BCs, we screened multiple drugs and found Pirfenidone, an FDA approved anti-pulmonary fibrosis drug (King et al., 2014) could facilitate the SOX9+ BC transplantation efficiency significantly.”
BackgroundBrindisi, M., Saraswati, A. P., Brogi, S., Gemma, S., Butini, S., & Campiani, G. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00924 · Cited by 111
Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis
Guler, S. A., Ellison, K., Algamdi, M., Collard, H. R., & Ryerson, C. J. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201801-067oc · Cited by 121
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis
Khalil, N., Manganas, H., Ryerson, C. J., Shapera, S., Cantin, A. M., Hernandez, P., Turcotte, E. E., Parker, J. M., Moran, J. E., Albert, G. R., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.00663-2018 · Cited by 109
Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
Kaunisto, J., Salomaa, E.-R. M., Hodgson, U., Kaarteenaho, R. L., Kankaanranta, H., Koli, K. M., Vahlberg, T. J., & Myllärniemi, M. (2019) · ERJ Open Research · doi:10.1183/23120541.00170-2018 · Cited by 123
Tanner, L., Single, A., Bhongir, R. K. V., Heusel, M., Mohanty, T., Karlsson, C. A. Q., Pan, L., Clausson, C.-M., Bergwik, J., Wang, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36314-5 · Cited by 123
Sheth, J. S., Belperio, J. A., Fishbein, M. C., Kazerooni, E. A., Lagstein, A., Murray, S., Myers, J. L., Simon, R. H., Sisson, T. H., Sundaram, B., et al. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.09.028 · Cited by 118
section, I., Žůrková, M., IPF registry, Kriegová, E., Kolek, V., Lošťáková, V., Šterclová, M., Bartoš, V., Doubková, M., Binková, I., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-0977-2 · Cited by 123
Pulmonary rehabilitation for interstitial lung disease
Dowman, L., Hill, C. J., May, A., & Holland, A. E. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006322.pub4 · Cited by 315
Advances and challenges in kidney fibrosis therapeutics
Abbad, L., Estève, E., & Chatziantoniou, C. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00934-5 · Cited by 148
Quantitative Proteomics of Bronchoalveolar Lavage Fluid in Idiopathic Pulmonary Fibrosis
Foster, M. W., Morrison, L. D., Todd, J. L., Snyder, L. D., Thompson, J. W., Soderblom, E. J., Plonk, K., Weinhold, K. J., Townsend, R., Minnich, A., et al. (2015) · Journal of Proteome Research · doi:10.1021/pr501149m · Cited by 108
Maher, T. M., Molina-Molina, M., Russell, A.-M., Bonella, F., Jouneau, S., Ripamonti, E., Axmann, J., & Vancheri, C. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0468-5 · Cited by 108
Kaushik, S. S., Freeman, M. S., Yoon, S. W., Liljeroth, M. G., Stiles, J. V., Roos, J. E., Michael Foster, W. S., Rackley, C. R., McAdams, H. P., & Driehuys, B. (2014) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00326.2014 · Cited by 107
The diagnosis of idiopathic pulmonary fibrosis: current and future approaches
Martinez, F. J., Chisholm, A., Collard, H. R., Flaherty, K. R., Myers, J., Raghu, G., Walsh, S. L. F., White, E. S., & Richeldi, L. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30325-3 · Cited by 107
Johannson, K. A., Vittinghoff, E., Morisset, J., Wolters, P. J., Noth, E. M., Balmes, J. R., & Collard, H. R. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.01.015 · Cited by 120
Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis
Hunninghake, G. M., Quesada-Arias, L. D., Carmichael, N. E., Manzano, J. M. M., Poli, S., Baumgartner, M. A., DiGianni, L. M., Gampala-Sagar, S., Leone, D. A., Gulati, S., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1571oc · Cited by 120
Duerr, J., Leitz, D. H. W., Szczygiel, M., Dvornikov, D., Fraumann, S. G., Kreutz, C., Zadora, P. K., Seyhan Agircan, A., Konietzke, P., Engelmann, T. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15743-6 · Cited by 107
Post-COVID-19 pneumonia lung fibrosis: a worrisome sequelae in surviving patients
Ali, R. M. M., & Ghonimy, M. B. I. (2021) · The Egyptian Journal of Radiology and Nuclear Medicine · doi:10.1186/s43055-021-00484-3 · Cited by 125
Althobiani, M. A., Russell, A., Jacob, J., Ranjan, Y., Folarin, A., Hurst, J. R., & Porter, J. C. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1296890 · Cited by 148
Ley, B., Bradford, W. Z., Vittinghoff, E., Weycker, D., du Bois, R. M., & Collard, H. R. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201508-1546oc · Cited by 106
Self-citationZhang, W., Ohno, S., Steer, B., Klee, S., Staab-Weijnitz, C. A., Wagner, D., Lehmann, M., Stoeger, T., Königshoff, M., & Adler, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01216 · Cited by 103
Fibroblast growth factor‐1 attenuates TGF‐β1‐induced lung fibrosis
Shimbori, C., Bellaye, P., Xia, J., Gauldie, J., Ask, K., Ramos, C., Becerril, C., Pardo, A., Selman, M., & Kolb, M. (2016) · The Journal of Pathology · doi:10.1002/path.4768 · Cited by 105
Li, T., Guo, L., Chen, Z., Gu, L., Sun, F., Tan, X., Chen, S., Wang, X., & Ye, S. (2016) · Scientific Reports · doi:10.1038/srep33226 · Cited by 117
Reactive oxygen species as signaling molecules in the development of lung fibrosis
Gonzalez-Gonzalez, F. J., Chandel, N. S., Jain, M., & Budinger, G. R. S. (2017) · Translational Research · doi:10.1016/j.trsl.2017.09.005 · Cited by 105
Mitochondrial Dysfunction in Pulmonary Fibrosis
Rangarajan, S., Bernard, K. F., & Thannickal, V. J. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201705-370aw · Cited by 116
on behalf of the IPF-PRO Registry investigators, Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1103-4 · Cited by 104
Spatial transcriptomic characterization of pathologic niches in IPF
Mayr, C. H., Santacruz, D., Jarosch, S., Bleck, M., Dalton, J., McNabola, A., Lempp, C., Neubert, L., Rath, B., Kamp, J. C., et al. (2024) · Science Advances · doi:10.1126/sciadv.adl5473 · Cited by 147
Interstitial Pneumonia with Autoimmune Features
Graney, B. A., & Fischer, A. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201808-565cme · Cited by 115
The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis
Bolourani, S., Brenner, M., & Wang, P. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02113-y · Cited by 134
Ni, K., Liu, M., Zheng, J. H., Wen, L., Chen, Q., Xiang, Z., Lam, K.-T., Liu, Y., Chan, G., Lau, Y., et al. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0326oc · Cited by 111
Interstitial Lung Abnormality: Recognition and Perspectives
Hatabu, H., Hunninghake, G. M., & Lynch, D. A. (2018) · Radiology · doi:10.1148/radiol.2018181684 · Cited by 103
Cellular senescence and radiation-induced pulmonary fibrosis
He, Y., Thummuri, D., Zheng, G., Okunieff, P., Citrin, D. E., Vujaskovic, Z., & Zhou, D. (2019) · Translational Research · doi:10.1016/j.trsl.2019.03.006 · Cited by 103
Interstitial Lung Disease in Scleroderma
Schoenfeld, S. R., & Castelino, F. V. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2014.12.005 · Cited by 103
Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis
Fisher, M., Nathan, S. D., Hill, C., Marshall, J., Dejonckheere, F., Thuresson, P.-O., & Maher, T. M. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.3-b.s17 · Cited by 103
Self-citationDelivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases
Newman, S. P. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.010 · Cited by 109
Machine learning in radiology: the new frontier in interstitial lung diseases
Barnes, H., Humphries, S. M., George, P. M., Assayag, D., Glaspole, I., Mackintosh, J. A., Corte, T. J., Glassberg, M. K., Johannson, K. A., Calandriello, L., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00230-8 · Cited by 119
Self-citationTreatment of idiopathic pulmonary fibrosis: a network meta-analysis
Rochwerg, B., Neupane, B., Zhang, Y., Garcia, C. C., Raghu, G., Richeldi, L., Brozek, J., Beyene, J., & Schünemann, H. (2016) · BMC Medicine · doi:10.1186/s12916-016-0558-x · Cited by 101
Idiopathic pulmonary fibrosis.
Koudstaal, T., & Wijsenbeek, M. S. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104166 · Cited by 105
Li, X., Zhu, L., Wang, B., Yuan, M., & Zhu, R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00855 · Cited by 108
Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
Kyung, S. Y., Kim, D. Y., Yoon, J. Y., Son, E. S., Kim, Y. J., Park, J. W., & Jeong, S. H. (2018) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-018-0204-7 · Cited by 110
Molina-Molina, M., Machahua-Huamani, C., Vicens-Zygmunt, V., Llatjós, R., Escobar, I., Sala-Llinas, E., Luburich-Hernaiz, P., Dorca, J., & Montes-Worboys, A. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0626-4 · Cited by 100
Raghu, G., van den Blink, B., Hamblin, M. J., Brown, A. W., Golden, J. A., Ho, L. A., Wijsenbeek, M. S., Vašáková, M., Pesci, A., Antin-Ozerkis, D. E., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30172-9 · Cited by 104
Udwadia, Z., Koul, P. A., & Richeldi, L. (2020) · Lung India · doi:10.4103/lungindia.lungindia_818_20 · Cited by 110
Raghu, G., Mouded, M., Chambers, D. C., Martinez, F. J., Richeldi, L., Lancaster, L. H., Hamblin, M. J., Gibson, K. F., Rosas, I. O., Prasse, A., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202112-2824oc · Cited by 100
Self-citationPirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
Chianese, M. I., Screm, G., Salton, F., Confalonieri, P., Trotta, L., Barbieri, M., Ruggero, L., Mari, M., Reccardini, N., Geri, P., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17060709 · Cited by 128
“To date, the pharmacological options for the treatment of IPF are Nintedanib and Pirfenidone, two drugs designed to slow disease progression that have shown to have similar effects in real life [6,7,31–36].”
BackgroundDempsey, T. M., Payne, S., Sangaralingham, L., Yao, X., Shah, N. D., & Limper, A. H. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202007-901oc · Cited by 101
Ushakumary, M. G., Riccetti, M., & Perl, A.-K. T. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0526 · Cited by 100
MUC5B and Idiopathic Pulmonary Fibrosis
Yang, I. V., Fingerlin, T. E., Evans, C. M., Schwarz, M. I., & Schwartz, D. A. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201503-110aw · Cited by 100
Koo, H. Y., El-Baz, L. M. F., House, S., Cilvik, S. N., Dorry, S. J., Shoukry, N. M., Salem, M. L., Hafez, H. S., Dulin, N. O., Ornitz, D. M., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5106 · Cited by 104
Gu, L., Larson Casey, J. L., Andrabi, S. A., Lee, J. H., Meza-Perez, S., Randall, T. D., & Carter, A. B. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101307 · Cited by 100
Aronson, K. I., Danoff, S. K., Russell, A.-M., Ryerson, C. J., Suzuki, A., Wijsenbeek, M. S., Bajwah, S., Bianchi, P., Corte, T. J., Lee, J. S., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202105-1193st · Cited by 99
Self-citationTang, H., Gao, L., Mao, J., He, H., Liu, J., Cai, X., Lin, H., & Wu, T. (2015) · Cell Stress and Chaperones · doi:10.1007/s12192-015-0654-4 · Cited by 105
“Encouragingly, pirfenidone (an antifibrotic and antiinflammatory agent) and nintedanib (a tyrosine kinase inhibitor) have recently been demonstrated to reduce the decline in forced vital capacity (King et al. 2014; Richeldi et al. 2014).”
BackgroundClinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study
Raimundo, K., Chang, E., Broder, M. S., Alexander, K., Zazzali, J., & Swigris, J. J. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0165-1 · Cited by 98
Self-citationWalsh, S. L. F., Maher, T. M., Kolb, M., Poletti, V., Nusser, R., Richeldi, L., Vancheri, C., Wilsher, M. L., Antoniou, K. M., Behr, J., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00936-2017 · Cited by 99
“Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med 2007; 175(10): 1054-60.”
BackgroundSelf-citationSAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772)
Raghu, G., Richeldi, L., Crestani, B., Wung, P., Bejuit, R., Esperet, C., Antoni, C., & Soubrane, C. (2018) · European Respiratory Journal · doi:10.1183/13993003.01130-2018 · Cited by 99
Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis
Balestro, E., Calabrese, F., Turato, G., Lunardi, F., Bazzan, E., Marulli, G., Biondini, D., Rossi, E., Sanduzzi, A., Rea, F., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154516 · Cited by 98
Fingerlin, T. E., Zhang, W., Yang, I. V., Ainsworth, H. C., Russell, P. H., Blumhagen, R. Z., Schwarz, M. I., Brown, K. K., Steele, M. P., Loyd, J. E., et al. (2016) · BMC Genetics · doi:10.1186/s12863-016-0377-2 · Cited by 98
Self-citationKurita, Y., Araya, J., Minagawa, S., Hara, H., Ichikawa, A., Saito, N., Kadota, T., Tsubouchi, K., Sato, N., Yoshida, M., et al. (2017) · Respiratory Research · doi:10.1186/s12931-017-0600-3 · Cited by 98
Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis
May, J. M., Mitchell, J. A., & Jenkins, G. R. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172058 · Cited by 115
FK506-Binding Protein 10, a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis
Staab-Weijnitz, C. A., Fernandez, I. E., Knüppel, L., Maul, J., Heinzelmann, K., Juan-Guardela, B. M., Hennen, E., Preissler, G., Winter, H., Neurohr, C., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201412-2233oc · Cited by 98
The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target
Steckelings, U. M., Widdop, R. E., Sturrock, E. D., Lubbe, L., Hussain, T., Kaschina, E., Unger, T., Hallberg, A., Carey, R. M., & Sumners, C. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000281 · Cited by 97
van den Blink, B., Dillingh, M. R., Ginns, L. C., Morrison, L. D., Moerland, M., Wijsenbeek, M., Trehu, E. G., Bartholmai, B. J., & Burggraaf, J. (2016) · European Respiratory Journal · doi:10.1183/13993003.00850-2015 · Cited by 97
End-of-life care of patients with idiopathic pulmonary fibrosis
Rajala, K., Lehto, J. T., Saarinen, M., Sutinen, E., Saarto, T., & Myllärniemi, M. (2016) · BMC Palliative Care · doi:10.1186/s12904-016-0158-8 · Cited by 97
Optimising experimental research in respiratory diseases: an ERS statement
Bonniaud, P., Fabre, A., Frossard, N., Guignabert, C., Inman, M. D., Kuebler, W. M., Maes, T., Shi, W., Stämpfli, M. R., Uhlig, S., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.02133-2017 · Cited by 104
Mitochondrial dysfunction contributes to the senescent phenotype of IPF lung fibroblasts
Schuliga, M., Pechkovsky, D. V., Read, J., Waters, D. W., Blokland, K. E. C., Reid, A. T., Hogaboam, C. M., Khalil, N., Burgess, J. K., Prêle, C. M., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13855 · Cited by 97
Maher, T. M., Kreuter, M., Lederer, D. J., Brown, K. K., Wuyts, W. A., Verbruggen, N., Stutvoet, S., Fieuw, A. M., Ford, P., Abi‐Saab, W., et al. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000422 · Cited by 105
“Subsequent pooled analyses of phase III trials have shown reductions in mortality.(14) 15 In addition, real-world registry data suggest improved survival in those treated with, versus without, antifibrotic treatments, regardless of baseline disease severity,(16) and pooled registry and clinical trial data suggest that…”
BackgroundSelf-citationTherapeutic Use of Extracellular Vesicles for Acute and Chronic Lung Disease
Worthington, E. N., & Hagood, J. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072318 · Cited by 100
Fibrosis: cross-organ biology and pathways to development of innovative drugs
Rieder, F., Nagy, L. E., Maher, T. M., Distler, J. H. W., Kramann, R., Hinz, B., & Prunotto, M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01158-9 · Cited by 154
A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis
Rosas, I. O., Goldberg, H. J., Collard, H. R., El‐Chemaly, S., Flaherty, K. R., Hunninghake, G. M., Lasky, J. A., Lederer, D. J., Machado, R. F., Martínez, F. J., et al. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.09.052 · Cited by 105
Self-citationAn ethnobotanical study of medicinal plants used to treat skin diseases in northern Pakistan
Malik, K., Ahmad, M., Zafar, M., Ullah, R., Mahmood, H. M., Parveen, B., Rashid, N., Sultana, S., Shah, S. N., & Lubna (2019) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-019-2605-6 · Cited by 71
Wuyts, W. A., Wijsenbeek, M., Bondue, B., Bouros, D., Bresser, P., Robalo Cordeiro, C., Hilberg, O., Magnusson, J., Manali, E. D., Morais, A., et al. (2020) · Respiration · doi:10.1159/000504763 · Cited by 96
Fibrometabolism—An emerging therapeutic frontier in pulmonary fibrosis
Selvarajah, B., Azuelos, I., Anastasiou, D., & Chambers, R. C. (2021) · Science Signaling · doi:10.1126/scisignal.aay1027 · Cited by 104
Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis
Jones, M. G., Fabre, A., Schneider, P., Cinetto, F., Sgalla, G., Mavrogordato, M., Jogai, S., Alzetani, A., Marshall, B. G., O’Reilly, K. M. A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86375 · Cited by 95
Combined inhibition of TGFβ and PDGF signaling attenuates radiation-induced pulmonary fibrosis
Dadrich, M., Nicolay, N. H., Flechsig, P., Bickelhaupt, S., Hoeltgen, L., Roeder, F., Hauser, K., Tietz, A., Jenne, J., Perez, R. L., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1123366 · Cited by 106
Richeldi, L., Varone, F., Bergna, M., de Andrade, J., Falk, J., Hallowell, R., Jouneau, S., Kondoh, Y., Morrow, L., Randerath, W., et al. (2018) · European Respiratory Review · doi:10.1183/16000617.0074-2018 · Cited by 95
Bing, P., Zhou, W., & Tan, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.865065 · Cited by 108
Cardiac Fibrosis in the Pressure Overloaded Left and Right Ventricle as a Therapeutic Target
Schimmel, K., Ichimura, K., Reddy, S., Haddad, F., & Spiekerkoetter, E. F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.886553 · Cited by 122
Yamagami, K., Oka, T., Wang, Q., Ishizu, T., Lee, J., Miwa, K., Akazawa, H., Naito, A. T., Sakata, Y., & Komuro, I. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00137.2015 · Cited by 106
Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF
Decaris, M. L., Schaub, J. R., Chen, C., Cha, J., Lee, G. G., Rexhepaj, M., Ho, S. S., Rao, V., Marlow, M. M., Kotak, P., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01863-0 · Cited by 94
Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review
Iqbal, K., & Kelly, C. A. (2015) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x15612250 · Cited by 107
Reddy, M., Fonseca, L., Gowda, S., Chougule, B., Hari, A., & Totey, S. (2016) · International Journal of Stem Cells · doi:10.15283/ijsc16041 · Cited by 93
Fibulin-1c regulates transforming growth factor–β activation in pulmonary tissue fibrosis
Liu, G., Cooley, M. A., Jarnicki, A., Borghuis, T., Nair, P. M., Tjin, G., Hsu, A., Haw, T. J., Fricker, M., Harrison, C. L., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124529 · Cited by 111
“Both drugs delay the impairment of lung function and improve the survival rate of patients with IPF (6, 15).”
BackgroundInfluential
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.